BioCentury | Dec 22, 2014
Company News

Cristal Therapeutics management update

...Cristianne Rijcken to CSO from CEO; she is succeeded by Joost Holthuis, formerly CEO of OctoPlus N.V....
BioCentury | Oct 13, 2014
Company News

Agendia management update

...the Netherlands Business: Diagnostic, Microarrays Hired: Jan Egberts, a director, as CEO, formerly CEO of OctoPlus N.V....
BioCentury | Mar 31, 2014
Finance

LSP's steady hand

...vaccines for infectious diseases Acquired by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) €250M ($323M) in cash May-13 OctoPlus N.V....
BioCentury | Nov 11, 2013
Company News

BioSpring, Dr. Reddy's, InteRNA Technologies, Quiet Therapeutics, Laboratory of Pharmacology and Toxicology (LPT) GmbH & Co. KG, VU University Medical Center ca

...consortium also includes BioSpring, which will provide miRNA synthesis services for the consortium; Dr. Reddy's OctoPlus N.V....
...drug product formulations; and LPT, a GLP-accredited toxicology laboratory that provides testing and consulting services. OctoPlus...
BioCentury | Mar 11, 2013
Company News

OctoPlus, Dr. Reddy's deal

...about 51.9 million shares, of OctoPlus. The companies are requesting NYSE Euronext Amsterdam to terminate OctoPlus'...
...or about €27.4 million ($36.1 million) (see BioCentury, Oct. 29, 2012 & Dec. 24, 2012). OctoPlus N.V....
BioCentury | Dec 24, 2012
Company News

OctoPlus, Dr. Reddy's deal

...Dr. Reddy's began a tender offer to acquire drug delivery company OctoPlus for €0.52 per share...
...Reddy's said it held about 41.7 million shares, or about 79.2% (see BioCentury, Oct. 29). OctoPlus N.V....
BioCentury | Oct 29, 2012
Finance

Highlights of weekly biotech stock moves

...series A preferred stock and a warrant to purchase one common share, exercisable at $2. OctoPlus N.V....
...in cash, or about €27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'...
...the deal was announced. Dr. Reddy's will begin a tender offer in December. Last week, OctoPlus...
BioCentury | Oct 29, 2012
Company News

OctoPlus, Dr. Reddy's deal

...Dr. Reddy's will acquire drug delivery company OctoPlus for €0.52 per share in cash, or about...
...in cash, or about €27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'...
...year 2012 ending March 31, 2012. OctoPlus had 2011 revenues of €7.7 million ($10 million). OctoPlus N.V....
BioCentury | Oct 23, 2012
Company News

Dr. Reddy's to acquire OctoPlus

...Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) will acquire drug delivery company OctoPlus N.V. (Euronext:OCTO) for EUR 0.52 per...
...cash, or about EUR 27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'...
...Friday, before the deal was announced. Dr. Reddy%27s will begin a tender offer in December. OctoPlus...
BioCentury | Jul 16, 2012
Company News

Biolex infectious news

...completed Phase II testing to treat HCV infection. Locteron uses PolyActive controlled-release delivery technology from OctoPlus N.V....
Items per page:
1 - 10 of 133
BioCentury | Dec 22, 2014
Company News

Cristal Therapeutics management update

...Cristianne Rijcken to CSO from CEO; she is succeeded by Joost Holthuis, formerly CEO of OctoPlus N.V....
BioCentury | Oct 13, 2014
Company News

Agendia management update

...the Netherlands Business: Diagnostic, Microarrays Hired: Jan Egberts, a director, as CEO, formerly CEO of OctoPlus N.V....
BioCentury | Mar 31, 2014
Finance

LSP's steady hand

...vaccines for infectious diseases Acquired by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) €250M ($323M) in cash May-13 OctoPlus N.V....
BioCentury | Nov 11, 2013
Company News

BioSpring, Dr. Reddy's, InteRNA Technologies, Quiet Therapeutics, Laboratory of Pharmacology and Toxicology (LPT) GmbH & Co. KG, VU University Medical Center ca

...consortium also includes BioSpring, which will provide miRNA synthesis services for the consortium; Dr. Reddy's OctoPlus N.V....
...drug product formulations; and LPT, a GLP-accredited toxicology laboratory that provides testing and consulting services. OctoPlus...
BioCentury | Mar 11, 2013
Company News

OctoPlus, Dr. Reddy's deal

...about 51.9 million shares, of OctoPlus. The companies are requesting NYSE Euronext Amsterdam to terminate OctoPlus'...
...or about €27.4 million ($36.1 million) (see BioCentury, Oct. 29, 2012 & Dec. 24, 2012). OctoPlus N.V....
BioCentury | Dec 24, 2012
Company News

OctoPlus, Dr. Reddy's deal

...Dr. Reddy's began a tender offer to acquire drug delivery company OctoPlus for €0.52 per share...
...Reddy's said it held about 41.7 million shares, or about 79.2% (see BioCentury, Oct. 29). OctoPlus N.V....
BioCentury | Oct 29, 2012
Finance

Highlights of weekly biotech stock moves

...series A preferred stock and a warrant to purchase one common share, exercisable at $2. OctoPlus N.V....
...in cash, or about €27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'...
...the deal was announced. Dr. Reddy's will begin a tender offer in December. Last week, OctoPlus...
BioCentury | Oct 29, 2012
Company News

OctoPlus, Dr. Reddy's deal

...Dr. Reddy's will acquire drug delivery company OctoPlus for €0.52 per share in cash, or about...
...in cash, or about €27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'...
...year 2012 ending March 31, 2012. OctoPlus had 2011 revenues of €7.7 million ($10 million). OctoPlus N.V....
BioCentury | Oct 23, 2012
Company News

Dr. Reddy's to acquire OctoPlus

...Dr. Reddy%27s Laboratories Ltd. (NYSE:RDY) will acquire drug delivery company OctoPlus N.V. (Euronext:OCTO) for EUR 0.52 per...
...cash, or about EUR 27.4 million ($35.7 million). The price is a 30% premium to OctoPlus'...
...Friday, before the deal was announced. Dr. Reddy%27s will begin a tender offer in December. OctoPlus...
BioCentury | Jul 16, 2012
Company News

Biolex infectious news

...completed Phase II testing to treat HCV infection. Locteron uses PolyActive controlled-release delivery technology from OctoPlus N.V....
Items per page:
1 - 10 of 133